Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harmine/DMT Molecular Imaging Study
NCT06252506Phase 1Completed
- Sponsor
- Insel Gruppe
- Start
- Jan 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DMT and harmine, sponsored by Insel Gruppe. Primary endpoint: Cerebral Metabolic Rate for Glucose up to 6 months. Started Jan 2024; status: completed.
02
Drugs
DMTharmine
Beyond the preview
Go deeper on NCT06252506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06252506.